{"name": "Merus",
 "permalink": "merus",
 "crunchbase_url": "http://www.crunchbase.com/company/merus",
 "homepage_url": "http://www.merus.nl/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2003,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "enquiries@merus.nl",
 "phone_number": "31 655 764 221",
 "description": "",
 "created_at": "Mon Feb 01 04:46:27 UTC 2010",
 "updated_at": "Wed Jul 21 01:30:06 UTC 2010",
 "overview": "\u003Cp\u003EMerus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       57],
      "assets/images/resized/0007/5586/75586v1-max-150x150.jpg"],
     [[164,
       63],
      "assets/images/resized/0007/5586/75586v1-max-250x250.jpg"],
     [[164,
       63],
      "assets/images/resized/0007/5586/75586v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Ton",
      "last_name": "Logtenberg",
      "permalink": "ton-logtenberg",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "\u20ac21.7M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.merus.nl/news/10/16/Merus-closes-EUR-21-7-million-Series-B-financing-and-enters-option-agreement-with-the-Novartis-Option-Fund.html",
    "source_description": "Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund",
    "raised_amount": 21700000.0,
    "raised_currency_code": "EUR",
    "funded_year": 2010,
    "funded_month": 1,
    "funded_day": 29,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Novartis Venture Fund",
         "permalink": "novartis-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0005/9083/59083v2-max-150x150.png"],
             [[250,
               117],
              "assets/images/resized/0005/9083/59083v2-max-250x250.png"],
             [[318,
               150],
              "assets/images/resized/0005/9083/59083v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company":
        {"name": "Pfizer",
         "permalink": "pfizer",
         "image":
          {"available_sizes":
            [[[82,
               55],
              "assets/images/resized/0005/9046/59046v1-max-150x150.png"],
             [[82,
               55],
              "assets/images/resized/0005/9046/59046v1-max-250x250.png"],
             [[82,
               55],
              "assets/images/resized/0005/9046/59046v1-max-450x450.png"]],
           "attribution": null}},
       "financial_org": null,
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Bay City Capital",
         "permalink": "bay-city-capital",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0004/8963/48963v1-max-150x150.png"],
             [[219,
               36],
              "assets/images/resized/0004/8963/48963v1-max-250x250.png"],
             [[219,
               36],
              "assets/images/resized/0004/8963/48963v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Life Sciences Partners",
         "permalink": "life-sciences-partners",
         "image":
          {"available_sizes":
            [[[146,
               66],
              "assets/images/resized/0004/7976/47976v1-max-150x150.jpg"],
             [[146,
               66],
              "assets/images/resized/0004/7976/47976v1-max-250x250.jpg"],
             [[146,
               66],
              "assets/images/resized/0004/7976/47976v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Padualaan 8 (postvak 133)",
    "address2": "",
    "zip_code": "3584 CH",
    "city": "Utrecht",
    "state_code": null,
    "country_code": "NLD",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        80],
       "assets/images/resized/0007/5585/75585v1-max-150x150.jpg"],
      [[250,
        134],
       "assets/images/resized/0007/5585/75585v1-max-250x250.jpg"],
      [[450,
        242],
       "assets/images/resized/0007/5585/75585v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}